PEPTONIC medical AB (publ) announced that Apotek Hjärtat is initiating sales of the company's leading intimate care product VagiVital® AktivGel in most of its physical stores in Sweden, starting in May. VagiVital® AktivGel is a treatment for vaginal atrophy and was the first product that Peptonic launched in intimate care. Peptonic intends to be a leading player in clinically proven intimate self-care, and there is a clear trend that people want to take greater responsibility for their own health with clinically proven self-care products.

VagiVital® AktivGel is already sold online by all Swedish pharmacy operators and in all physical pharmacies with the exception of Apotek Hjärtat. The market for this type of treatment is growing by about 10% per year. In 2022, VagiVital AktivGel grew by more than +50% in Sweden compared to 2021 and increased its market share significantly, a growth that also forms the basis for Apotek Hjärtat's decision to now bring VagiVital® AktivGel into ca 300 of its 400 physical stores, which represent just under 30% of the total number of physical pharmacies in Sweden.